New drug trial for kids with severe psoriasis shows promise

NCT ID NCT03240809

Ongoing Disease control Sponsor: Bausch Health Americas, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a single dose of brodalumab in children aged 6 to 17 with severe plaque psoriasis. The goal is to see how safe the drug is and how the body processes it. Only 2 children are enrolled, making this a very early look at the drug's effects in younger patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brodalumab
What this could lead to: If successful, this could provide a treatment option for children with severe psoriasis, helping to control their symptoms.
What could go wrong: This is a very small, early-phase study with only 2 participants, so results may not apply to all children. The drug may cause side effects or not work as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Locations

Bausch Site 001

Las Vegas, Nevada, 45242, United States
Bausch Site 002

Miami, Florida, 33155, United States
Bausch Site 003

San Diego, California, 92123, United States
Bausch Site 004

Miami, Florida, 33155, United States
Bausch Site 005

Henderson, Nevada, 89052, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.